Parabilis Medicines Initiates Dose-Ranging Clinical Study of Zolucatetide in Familial Adenomatous Polyposis
Globe Newswire•14/10/2026•07:00 ET
0
Key Highlights
- ➤Dose-ranging FAP cohort initiated within Parabilis’ ongoing Phase 1/2 zolucatetide trial
- ➤Two FAP patients showed significant duodenal polyp reductions, including Stage IV to near-normal
- ➤Additional FAP and desmoid tumor data expected in first quarter of 2027
- ➤Zolucatetide has demonstrated a favorable safety and tolerability profile to date
Expert Statements
Mathai Mammen, Chairman, CEO and President of Parabilis Medicines
“People with FAP face a lifetime of surveillance, repeated procedures and major surgeries, all while living with the persistent risk of cancer.”
Mathai Mammen, Chairman, CEO and President of Parabilis Medicines
“We believe a medicine that addresses the underlying biology of the disease has the potential to change that trajectory.”
Mathai Mammen, Chairman, CEO and President of Parabilis Medicines
“FAP is driven by loss of APC and the resulting persistent activation of Wnt/β-catenin signaling, making direct inhibition of the β-catenin:TCF interaction the most direct therapeutic approach to reversing the causal biology of the disease.”
Mathai Mammen, Chairman, CEO and President of Parabilis Medicines
“We are highly encouraged by the significant reductions in precancerous duodenal polyp burden we have observed with zolucatetide in our first patients with FAP.”
Mathai Mammen, Chairman, CEO and President of Parabilis Medicines
“The initiation of this dose-ranging study reflects our growing confidence in zolucatetide’s potential to fundamentally change the treatment of FAP and is an important step toward defining the dose and schedule we intend to take into registrational development for this devastating disease.”
New dose-ranging cohort in FAP builds on compelling early clinical evidence observed with zolucatetide in patients with FAP and concomitant desmoid tumors
Zolucatetide directly inhibits β-catenin:TCF, targeting the APC-mutation biology that drives precancerous adenomatous polyp formation in patients with FAP
Get started
Create a free account to read the full story.